OKYO Pharma Limited (OKYO) Stock Score, Valuation & Financial Research

OKYO Pharma Limited is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for OKYO

OKYO Pharma Limited does not currently have a complete Wall Street Score. The stored market price is USD 1.43. These figures are a research snapshot, not a buy or sell recommendation.

What OKYO Pharma Limited does

OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.

Company business and revenue

Research reporting period: 2026-03-31. A research update is not a new financial filing.

How the company makes money

OKYO Pharma is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings to fund the research, development, and clinical trials of its proprietary drug candidates, such as urcosimod, for the treatment of ophthalmic diseases.

Products and services

  • The company is developing urcosimod (formerly OK-101), a first-in-class, lipid-based, non-opioid, anti-inflammatory drug candidate for the treatment of neuropathic corneal pain and other anterior segment eye diseases.

Brands and product families

  • urcosimod — Lead clinical-stage drug candidate for neuropathic corneal pain. Source

Customer types

Healthcare providers and patients with neuropathic corneal pain.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company engages various third-party contract research organizations to manage and conduct its clinical trials and preclinical studies. Source

Business strengths to evaluate

  • Strengthened cash position following successful public offerings Source

Business risks and research considerations

  • History of operating losses and dependence on additional financing to continue operations Source
  • Clinical trial failure or delays in regulatory approval processes Source

Sources: Company research source · Strengthened cash position following successful public offerings

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

OKYO financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.43
Market capitalization:
54.86M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -13.66M
Free cash flow:
USD -5.94M
Cash:
USD 14.59M
Total debt:
USD 0.00
EPS:
USD -0.36

What stands out

  • Free cash flow is USD -5.94M, negative for the stored period.
  • The balance sheet shows USD 14.59M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 14.59M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for OKYO

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can OKYO fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is OKYO likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for OKYO to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of OKYO's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-12.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research OKYO

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.